X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD).
Lead Product(s): Radix Polygalae extract,PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1505
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The patent application outlines a method for treating major depressive disorder by the patient’s oral administration of a composition containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421).
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Last patient last visit (LPLV) marked the final step toward the completion of ABV-1505 Phase II Part I clinical trial in treatment of adult attention-deficit hyperactivity disorder (ADHD).
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1505
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California. Primary objective of clinical trial is to determine the effective dosage of ABV-1505 in treatment of adult attention-deficit hyperactivity disorder (ADHD).
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD).
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
First of six patients has been enrolled for Phase II Part I trial of ABV-1505 at the University of California, San Francisco (UCSF) Medical Center.
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
